Podcasts about Zimmer Biomet

Solomon Wilcots joined us to talk abou the Bengals on behalf of Zimmer Biomet.Learn more about Zimmer Biomet at PickleballKnee.comPodcasts of The Mo Egger Radio Show are a service of Longnecks Sports Grill.Listen to the show live weekday afternoons 3:00 - 6:00 on ESPN1530. Listen Live: ESPN1530.com/listenGet more: https://linktr.ee/MoEggerFollow on X: @MoEggerInstagram too: @MoEgger

Send us a textJoin our host, Dr. Byron Stephens, as he speaks with Dr. Michael Kelly and Dr. Steven Glassman, two of the authors of Scoliosis Research Society–funded research recently published in the Journal of American Medical Association -- Surgery. Congratulations to all the authors on this outstanding achievement!The study, Long-Term Outcomes of Operative Versus Nonoperative Treatment for Adult Symptomatic Lumbar Scoliosis (ASLS): Durability of Treatment Effects and Impact of Related Serious Adverse Events Through 8-Year Follow-Up, was published in the Journal on April 2, 2025.To bring the study to its full 8-year follow up allowing for the JAMA publication, funding was provided by the SRS and several of the SRS industry partners and the International Spine Study Group . The SRS community and the study investigators appreciate the additional investments provided above and beyond their support of SRS, made by Globus Medical, K2M/Stryker Spine, Medtronic, NuVasive, and Zimmer Biomet.*The Scoliosis Research Society (SRS) podcast is aimed at delivering the most current and trusted information to clinicians that care for patients with scoliosis and other spinal conditions. From news in the world of spinal conditions, to discussions with thought leaders in the field, we aim to provide up-to-date, quality information that will impact the daily practice of spinal conditions.

Elon Musk returns for unexpected second sit-down with our David Faber. The wide-ranging interview touches on xAI, securing power for AI, the battle for chips supremacy and more.  We have instant takeaways with Walter Isaacson, author of Elon Musk, for a deeper look at the man behind the headlines then Roth Capital's Craig Irwin breaks down the stock implications for Tesla and the EV space. Plus, market sentiment check with Wells Fargo's Scott Wren and Payne Capital's Courtney Garcia and Zimmer Biomet CEO Ivan Tornos from the CNBC CEO Summit.

The show kicked off with Alan Morrissey chatting to John O'Brien and Tony Cogan about the Restaurants Association of Ireland's Cost of Doing Business 2025 Survey. Next, Alan spoke with Manufacturing Director of Ireland Operations, Tom O'Carroll and EMEA VP of QARC & Reg. Affairs, Frank Moloney. They discussed all things Zimmer Biomet. The conversation then shifted to Miltown Malbay AirBnB host, Lorna Cahill. She joined us on Morning Focus to discuss the remarkable finding from new research by Airbnb. Later, Alan was joined by Engineering Manager, Linda Phillips, Senior Chemist, Ahmad Ziaee and Chemist, Neville Murphy. They all chatted to Alan about the new investment on the talent development and retainment in the southwest region specifically Shannon, Clare. This was followed by the weekly Garda Focus segment with Sergeant Edel Burke, from Kilrush Garda Station. To follow, Alan was joined by Avril Collentine, Solicitor at Cahir & Co for our Legal slot. Next was our weekly episode of In the Garden Slot with Tom Stewart from Keanes Garden Centre. Derek Clune from Shannon Tidy Towns joined Alan to discuss How Zimmer has been involved in Shannon Tidy Towns, followed then by Operations Manager from Clare GAA, Deirdre Murphy. Deirdre discussed The partnership between Zimmer Biomet & Clare GAA. Next, Alan was joined by Manufacturing Director of Shannon operations, Mike O'Malley. Mikey chatted about CSR engagement in the surrounding Communities. Alan also caught up with Tommy Marren who discussed his latest play to Clare, Matches and Old Flames Back At Glór. Alan was then joined by Clare FM's, Derrick Lynch and Paudie Carmody to get the Sports Review from the Weekend. They discussed Kerry vs Clare and Waterford vs Clare. To wrap the show up, Alan was joined by Frankie Coote for the weekly ‘Ask the Dog Warden' segment.

Should the United States delist Chinese stocks? At first thought with all the craziness of the trade war it sounds like delisting all the Chinese companies from the American stock markets may be a good idea. It is important to know that there are 286 Chinese companies listed on major US stock exchanges. You'll recognize some of the names like Alibaba, Baidu and JD.com. It is estimated by analysts at Goldman Sachs that US institutional investors currently own about $830 billion worth of Chinese stocks. That is more than two times what the Chinese own of US stocks as that is estimated around $370 billion. But a quick sell off could bring down stock valuations and make it difficult to get out of many of these stocks on both sides. An important piece of information I brought up a couple years ago was the Accountable Act which came to be in 2020. This allows the Securities Exchange Commission to ban foreign companies from trading if American regulators are not allowed to inspect the auditors for three years in a row. I always worry about Chinese companies because of what I call government accounting. They are not held to the same accounting standards there and I believe companies may list financial statements based on what the government tells them. There have been some Chinese companies that delisted themselves rather than going through an audit. I think that tells you quite a bit. My feeling is we should not delist all the Chinese stocks that trade on American stock exchanges under what is known as ADRs, but be sure that the Chinese companies have the same transparency as American companies when it comes to their financial statements. If we can't get that transparency, then those companies should be delisted.    Jobs report shows more evidence the economy is in good shape US nonfarm payrolls grew by 177k in the month of April, which easily topped the estimate of 133k. Jobs remained robust in health care as the sector added 51k jobs in the month of April and employment in transportation and warehousing and financial activities was also strong as the groups added 29k and 14k jobs respectively in the month. Other categories like construction, manufacturing, leisure and hospitality, and retail trade saw little or no change in payrolls, while government declined by 9k jobs in the month. Government jobs are now down by 26k since January, but remember employees on paid leave or receiving ongoing severance pay are still counted as employed. This likely means we will continue to see losses accelerate in this category as the year continues. Negatives in the report included the fact that employment numbers were revised down by a total of 58k in the previous two months. Also, April's reading was lighter than March's reading of 185k, but considering the unemployment rate remains at 4.2%, I still see these jobs gains as impressive, especially with all the negativity that people have been discussing. With that said, I still do anticipate weaker numbers in terms of the payroll additions in future months, but if the unemployment rate remains low I don't see that as a problem. On the inflation front, we also got good news with average hourly earnings rising just 3.8%. I see this as a healthy increase that does not put pressure on inflation like when wages were growing over 5% in 2022.     Job openings look problematic on the surface In the March Job Openings and Labor Turnover Survey, job openings totaled 7.2 million. This was below February's reading of 7.5 million and the estimate, which also stood at 7.5 million. This is still not super concerning to me. We tend to forget how strong the labor market has been and while we continue to see a softening, there is plenty of room before I see cause for concern. Just for reference, job openings in 2019 averaged approximately 7.2 million, in 2018 they averaged approximately 6.8 million, and in 2017 they averaged approximately 6.2 million. Compare that to where we are today and that should give you more comfort. Another area I saw as positive in the report was the fact that quits totaled 3.3 million, which produced a quit rate of 2.1%. This is important because if people were truly concerned about a major slowdown and thought they would not be able to find work elsewhere, I don't believe they would be quitting their jobs. These quit numbers are still quite close to 2019 levels, which many considered as a very strong economy. That year quits averaged approximately 3.5 million and there was an average quit rate of about 2.3%. Also in the report, we saw layoffs remained quite low at 1.6 million. Back in 2019, layoffs averaged around 1.8 million per month. There is no doubt that uncertainty remains and that will have some impact on businesses and their hiring plans, but in terms of it pushing the economy into a major recession, since we are coming from such a healthy level, I just don't see that happening.   Are we in the middle of a recession? The first reading of Q1 GDP showed a decrease of 0.3%. A recession is generally defined as two consecutive quarters of declining GDP, so some may argue we are half way there. Let us not forget in 2022 we did see two consecutive quarters of declining GDP as Q1 declined 1.4% and Q2 showed an advance estimate that was down 0.9%. After further research the second quarter ended up seeing a total reversal and it is now reported to have actually grown by 0.3%. Even with the difficult start, that year ended with a 2.1% growth rate. We also can't forget that the National Bureau of Economy Research (NBER) makes the official call on recession and they use a broader set of indicators that led them not to declare a recession in 2022. I say all of this because I still believe even if we hit a technical recession, if employment remains strong, I don't believe we would have an “official” recession. I am still unsure that we will even see Q2 GDP decline and we could also see revisions to Q1 that lift it to a positive reading. I say this because if you look at the actual underlying numbers in the report, it is not nearly as bad as the headline decline. On the positive front, consumer spending actually grew 1.8% in the quarter as services showed a nice increase of 2.4%. Also, private domestic investment saw a surge of 21.9%, this was led by investments in equipment as they grew 22.5% in the quarter. You might be asking with numbers like these how did we see a negative GDP? To start, government spending fell 1.4% in the quarter. This was led by a decline of 5.1% in spending by the federal government. The group as a whole ended up subtracting 0.25% from the headline GDP number. While this was impactful, the real reason for the decline in GDP was trade. Companies were trying to get ahead of looming tariffs and imports surged 41.3%. This compared to an increase of just 1.8% for exports. The huge discrepancy caused the trade component of GDP to decrease the headline number by 4.83%! While the economy is no doubt digesting these trade conversations and the tariffs, I still believe the economy is in alright shape when you look at the underlying numbers. I did also want to mention more good news on inflation as the March headline PCE showed an increase of 2.3%, which compares to last month's reading of 2.7% and core PCE came in at just 2.6%, which was a nice decline from February's reading of 3.0%. I believe these numbers will likely increase with the tariffs, but underlying inflation looks to be quite healthy.   Financial Planning: Protecting Yourself from Home Title Theft Home title theft is a type of real estate fraud where someone illegally transfers the ownership of your home by forging your name on title documents.  This is often done using stolen personal information to file fraudulent deeds with the county recorder's office. Once the title appears to be in their name, the thief may try to take out loans against the property, sell it to an unsuspecting buyer, or use it in other schemes that could put your home and finances at risk. This crime can go undetected for months if property owners aren't actively monitoring their title.  Having a mortgage or HELOC on your house can make it more difficult for a thief to steal your title since the bank has a lien against the property, but it is still possible. There are private companies that charge monthly fees to alert you of changes to your home title, but they do not prevent the title from being stolen.  You can also purchase home title insurance that will help pay for legal fees if you have to go to court if your title is stolen.  Homeowners in San Diego County can access a free alternative called “Owner Alert”. Jordan Marks who is the San Diego County Assessor/Recorder/County Clerk was behind this, and it is a great benefit that all San Diego property owners should take advantage of.  This service works by notifying you by email whenever a document is recorded against your property, helping you catch potential fraud early.  Signing up is simple and can be done on the San Diego County Assessor's website. You just need your name, email address, and parcel number and it provides the same type of monitoring offered by paid services, making it unnecessary to spend money for peace of mind when this tool is already available for free.   Companies Discussed: Zimmer Biomet Holdings, Inc. (ZBH), Take-Two Interactive Software, Inc. (TTWO), Northrop Grumman Corporation (NOC)Alphabet Inc. (GOOG)

In this episode of the DeviceTalks Weekly podcast, Host Tom Salemi interviews Alan Lotvin, MD, the CEO and co-founder of Sequel Med Tech, a small company promoting another BIG idea from prolific inventor Dean Kamen. Lotvin, who was formerly a senior executive at CVS/Caremark and PBMs, explains how Twiist, the automated insulin delivery system, could be a game-changer for people with diabetes. Before the interview, we'll hear from Ivan Tornos, the CEO and president of Zimmer Biomet. Tornos, who is the opening keynote interview guest at DeviceTalks Boston on April 30 at the Boston Convention & Exhibition Center talks with Salemi and Joe Mullings about the the changes at Zimmer Biomet and in orthopedics. Register to see Tornos live at Boston.DeviceTalks.com. Use the code mentioned in the podcast to save 25%. Thanks for listening to the DeviceTalks Weekly Podcast. Subscribe to the DeviceTalks Podcast Network so you don't miss a future episode.

Opening its doors with just four toolmakers 50 years ago, Smithstown Light Engineering Ltd is now a business with three manufacturing sites and over 165 employees. Working with the world's leading medical device and orthopaedic companies, Smithstown extensively uses OPEN MIND Technologies‘ hyperMILL CAD/CAM suite to streamline its throughput and maximise efficiency. Initially a toolmaking business supplying plastic injection moulds to the electronics industry, the Shannon-based business transitioned to medical manufacturing in 1990—and it hasn't looked back since. With two sites in Shannon spanning 80,000sq/ft and a third 15,000sq/ft facility in Poland, 75% of the company's technology is less than 5 years old. Certified to ISO: 9001, ISO:13485 and ISO:14001, Smithstown has a bank of Citizen sliding head turning centres, in-house heat treatment, Rollomatic, Jung and Jones & Shipman grinding centres, DMG MORI and Mikron machining centres, Trumpf 3D additive manufacturing and Makino EDM technology. Working with renowned clients such as Stryker, Boston Scientific, Zimmer Biomet, and Cook Medical, to name a few, the company provides a turnkey service from concept and design through prototyping, machining, and validation of medical components and orthopaedic implants. With over 14 million components manufactured annually, the Irish manufacturer adopts stringent quality measures that are a necessity for ultra-precision medical device parts used in life-saving surgery. Alluding to his role within the company and a background in Smithstown Engineering, Gerard Henn from Smithstown Light Engineering says: “I've been here now nearly three years in the role of CEO, and I support the principal director of the business in the running of the operation. Smithtown started in 1974, so we are now 50 years in existence. Our principal area of expertise is precision machining to impeccable quality levels with customer service. We really pride ourselves in supporting the customer in all their difficulties and all their successes.” Manufacturing high precision parts to stringent standards, Gerard alludes to why the County Clare company opted for hyperMILL from OPEN MIND Technologies: “There are so many different options in the marketplace, but OPEN MIND made it much easier for us to work forward with hyperMILL. The explanation of the facets, the features, and how we could optimise our machining strategies and cutting paths – it has everything. That worked in our favour. The relationship with OPEN MIND and its hyperMILL system came together and created a partnership with us.” When Gerard joined the company, one of his aims was to upskill the staff, which was a critical necessity considering the shortage of skilled engineers. Alluding to this, Gerard adds: “OPEN MIND were very enthusiastic and got behind us. They understood what we were trying to achieve, and it's been a positive relationship all the way through. We'd recommend OPEN MIND to any companies out there who are interested in upskilling their internal workforce – the partnership has been extremely positive.“ Looking closer at the types of work the company is involved in, Gerard continues: “We operate in the medical space, and we support the orthopaedic and medical device companies in Ireland and also globally. We also do instrumentation for procedures, so it's very much a medical-focused enterprise.” Occupying a large floor area and two facilities, the company is continually evolving. Gerard adds: “So, we have over 200 employees and two sites here in Shannon. The second site is just literally 1 kilometre down the road, so you find us trekking up and down quite a bit, but you see the same technologies and approach in both buildings. We have a third facility in Rzeszów, Poland, a business that's been operating for 3 to 4 years. We also recently announced a major expansion there.“ “What we find in any process development is you're going through an iterative process. You're optimising the machining and cutting process, checking dimensions back to the machine to the virtual CAD station, and bringing all that together. So, I think the fact that OPEN MIND has supported us so much means we have a great understanding of hyperMILL. The upskilling is well in parallel and enables us to bring all the strands together to succeed. By success, I mean that we can deliver parts to specification earlier. That is because that's what everyone wants. Customers want parts in their hands, and having that collaboration of everyone allows us to achieve that.”

As you heard us mention on Friday's Morning Focus, and during our news bulletins this morning, Clare GAA has announced a multi-year deal for naming rights on the county grounds. Shannon-based company Zimmer Biomet has come on board as the new title sponsors, with the home of Clare GAA now being rebranded as Zimmer Biomet Páirc Chíosóig It is the first time that a sponsorship deal has been secured for the grounds, with the arrangement set to be in place for the next three years, with the option to extend for a further two. To discuss this further, Alan Morrissey was joined by Clare GAA's Chief Operating Officer, Deirdre Murphy, and Head of Manufacturing at Zimmer Biomet Shannon, Michael O'Malley. Photo (C): Clare FM

In this episode of Inside INdiana Business with Gerry Dick, we examine the lasting impact of the NFL Combine on Indianapolis. With the event injecting an estimated $9 million into the local economy, we explore how restaurants like St. Elmo Steakhouse and hotels across downtown are benefiting, and what it means for the city's future as a major sports hub. Plus, the Combine is more than just an athletic showcase - it's a proving ground for Indiana's growing sports technology sector. We sit down with executives from Sportable and SportsTech HQ to discuss how cutting-edge innovations in smart ball technology and data analytics are positioning Indy as a global leader in sports tech. Also in this episode: The future of the NFL Combine in Indianapolis: With its contract expiring in 2026, what's being done to keep the event in town? Arnold Schwarzenegger's Indiana connection: The action star joins forces with Warsaw-based Zimmer Biomet to motivate those with joint pain to seek treatment. Inside Jim Irsay's multimillion-dollar collection: A rare behind-the-scenes look at the Colts owner's legendary artifacts, from historic guitars to cultural treasures. Indy's hotel boom: Over $1 billion in investment is reshaping the skyline, with new luxury hotels fueling the city's convention industry. Fort Wayne FC goes pro: The city's soccer team leaps USL League One, with a new stadium on the horizon. Join us for an in-depth look at the business of sports, healthcare innovation, and Indiana's evolving economic landscape.

In this episode of the DeviceTalks Weekly Podcast, Host Tom Salemi talks with Highridge CEO Rebecca Whitney and Executive Chairman Eric Major about the swirling spinal market. Whitney and Major share what makes the spine industry different from other MedTech sectors and why they believe Highridge is uniquely positioned to grab a large piece of the market. The episode is sponsored by DeviceTalks Boston. Register to attend at Boston.DeviceTalks.com. DeviceTalks listeners can find our first interview with the Highridge team here. https://www.devicetalks.com/hear-highridge-medicals-plans-to-scale-the-spine-market-a-preview-of-the-medtechvision-conference/ MassDevice Editor Chris Newmarker returns with the Newmarker's Newsmakers sharing stories about Stereotaxis, the FDA, Philips, Zimmer Biomet, and Stryker. Thanks for listening to this episode of the DeviceTalks Weekly Podcast. Subscribe to the DeviceTalks Podcast Network so you don't miss a future episode.

In this episode of the Med-Tech Talent Lab podcast, host Mitch Robbins interviews Jeff Gensler, the Vice President of Quality at Kindeva Drug Delivery, about the innovative 'Frame by Frame' approach to manufacturing processes. Jeff's background spans over 20+ years of experience in Med-Tech Regulatory & Quality having held prominent positions with companies like Dentsply, Zimmer Biomet, and others prior to joining Kindeva. Jeff explains how this method revolutionizes process development by breaking down procedures into micro-steps and utilizing AI for risk assessment and training. The conversation covers the origins of this approach, its implementation in aseptic processing, and the significant time and cost savings it offers. Jeff also discusses the impact on roles within the industry, the feedback received from peers, and his personal journey in quality assurance. Tune in to learn about this revolutionary way of developing & implementing processes. Your views & approach will be forever changed....for the better!Jeff Gensler on LinkedIn:https://www.linkedin.com/in/jeff-gensler-67a54a1a/Kindeva Drug Delivery on the web:https://www.kindevadd.com/

This episode features Dave Rosa, CEO of NeuroOne, a company leading the way in innovative solutions for various neurological disorders. The discussion highlights the significant challenges faced by patients with epilepsy, particularly those whose condition is resistant to medication. Traditional treatment often involves multiple invasive surgeries, placing a significant physical and emotional burden on patients.NeuroOne has developed a groundbreaking technology that integrates both diagnostic and therapeutic functions into a single device. This innovative approach enables physicians to identify the source of seizures and then immediately proceed with ablation of the affected brain tissue within a single surgical procedure, minimizing patient discomfort and hospital stays. We explore the strategic partnership with Zimmer Biomet that has been pivotal for NeuroOne's successful market access, helping accelerate commercialization. With additional data insights, and future pharma collaboration opportunities, the future is truly bright for Dave and the team. NeuroOne is helping advance the movement towards personalized medicine, offering hope for improved patient outcomes, a story sure to leave you informed and inspired.

Today, we speak with Caroline Ristroph. Caroline Ristroph is a senior at Purdue University studying Biomedical Engineering. She graduated from The Woodlands High School in 2021. Caroline is currently completing a year-long Co-Op rotation at Cook Research Incorporated in West Lafayette, Indiana. As a Research and Development Engineering Intern, she works on minimally invasive medical devices in the Critical Care and Urology sectors. Before starting the Co-Op, Caroline spent her summer working at Zimmer Biomet as an Operations Intern in Warsaw, Indiana. In this role, she worked in orthopedic hip and knee implant manufacturing. At Purdue, she has been involved in Chi Omega and the Purdue Women's Volleyball Club, as well as worked as a Teaching Assistant for a Leadership Development class. After completing the Co-Op, she will finish her last semester at Purdue and graduate in December of 2025.

Northeast Indiana's continued growth This week, we are in Fort Wayne for our Engage Indiana series. We talk with business and community leaders about projects transforming the city and region like never before. We also talk with Fort Wayne-based Do It Best CEO Dan Starr about the just completed acquisition of True Value, creating the “largest hardware cooperative on the planet.” The Terminator joins Warsaw company Arnold Schwarzenegger is officially on the Zimmer Biomet payroll in a new position created just for him. It's one of the biggest orthopedic medical device companies in the world and the first to sign on a celebrity. Indianapolis Omni Severin Hotel's $24M makeover The oldest luxury hotel in downtown Indianapolis has unveiled a new look. We'll show you the new art deco style and how it honors the hotel's history. The Story of Sweetwater Sweetwater, the largest music retail company in the nation, was founded in Fort Wayne. Chuck Surack, who joined our Engage Northeast Indiana panel, shares the story of its path to success.

Kate Willis is an esteemed leader in Healthcare and MedTech, known for her strategic prowess and innovative approaches. Currently, she serves as the Vice President of Commercialization at Neurovalens, responsible for leading all global and US commercial functions, including the US launch. Her career highlights include serving as the Director of Government Affairs and Advocacy, where she has been a powerful force in shaping industry standards and policies.Kate's robust track record of leadership extends through premier companies such as Nevro, Medtronic, Nuvasive, and Zimmer Biomet, where her initiatives have not only spurred organizational growth but have also earned her multiple accolades. These honors include prestigious recognitions such as multiple President's Club awards, Sales Rep of the Year, and Rookie of the Year. Beyond her healthcare expertise, Kate is a recognized figure in the arts as a producer and investor, with successful ventures in Broadway, West End, and film productions. Her unique flair for bridging the realms of business and entertainment underlines her diverse capabilities and visionary outlook. SHOWNOTES:

In this episode of the DeviceTalks Weekly Podcast, Host Tom Salemi interviews Marwan Berrada, founder and managing partner of Santa Clara-based T45 Labs about how incubators can start new companies at a time when early-stage funding is scarce. MassDevice Editor Chris Newmarker deliveres his Newmarker's Newsmakers including GE HealthCare, Zimmer Biomet, Momentis Surgical, Johnson & Johnson MedTech and, of course, the news surrounding HHS. This episode is sponsored by DeviceTalks Boston. Register at Boston.DeviceTalks.com. Thanks for listening to the DeviceTalks Weekly Podcast. Subscribe to the DeviceTalks Podcast Network so you don't miss a future episode.

The major averages hovered near the flatline on Wednesday as the postelection rally lost some steam and traders contemplated a key inflation report that was in line with expectations. We'll track the market action.Plus, Zimmer Biomet (ZBH), a global medical technology leader in orthopedics, is partnering with Arnold Schwarzenegger, who will take on the newly established role of Chief Movement Officer. We'll speak to Arnold & the ZBH CEO.

In this week's episode, Dr. Scott Sigman sits down with Dr. Ryan Krupp, a private practice orthopedic surgeon. Here, they discuss his teaching endeavours across multiple disciplines, his passion for research, his involvement in design and industry with Zimmer Biomet, and more.

In this episode, Scott Becker discusses five stocks that faced significant declines, including Tempus AI, Coinbase, Tesla, McKesson, and Zimmer Biomet, each reflecting key trends in healthcare, AI, and the broader market. He also shares gratitude for the podcast's top ranking on Apple Business News.

In this episode, Scott Becker discusses five stocks that faced significant declines, including Tempus AI, Coinbase, Tesla, McKesson, and Zimmer Biomet, each reflecting key trends in healthcare, AI, and the broader market. He also shares gratitude for the podcast's top ranking on Apple Business News.

In this episode of the DeviceTalks Weekly podcast, HighRidge Medical CEO Rebecca Whitney and Executive Chairman Eric Major introduce us to the spine industry's newest player. HighRidge combines the former spinal business of Zimmer Biomet (and later ZimVie) with seasoned executive spirit from K2M, Stryker and others. Can HighRidge compete? Will robotics and other tech be part of the story? Whitney has been on podcasts before. Listen here https://www.youtube.com/watch?v=6xtHK-FVeec and here https://youtu.be/0Ve_7NpIauQ?si=Wp-ytFHlq4ZWHeCC. Host Tom Salemi and DeviceTalks Editor Kayleen Brown chat with MedtechVISION co-chairs Kate Stephenson, PhD, and Shelia Shah about the upcoming conference organized by the MedtechWOMEN group. A few spaces are still available. Go to MedtechWOMEN.org to register. Thanks for listening to the DeviceTalks Weekly Podcast. Subscribe to the DeviceTalks Podcast Network so you don't miss a future episode.

In this episode of Ortho Innovation Talks, Jim Lancaster, President of Global Reconstruction at Zimmer Biomet, connects his deep roots in Warsaw, Indiana—known as the orthopedic capital of the world—with his current role in shaping the region's future as a global MedTech hub with his efforts to diversify the region's medtech industry, including the partnership with Plug and Play to attract new innovations in sensor technology and augmented reality, and by driving technical innovations at Zimmer Biomet. Additionally, Lancaster provides an in-depth look at the development of Persona IQ, the world's first smart knee system, which integrates advanced sensor technology to monitor patient recovery. He also discusses the growing importance of cementless fixation in knee implants, highlighting Zimmer Biomet's focus on enhancing implant longevity and patient outcomes. Lastly, Lancaster discusses Zimmer Biomet's role in surgical robotics, particularly the advancements brought by the Rosa robotics platform, which includes applications for knee, hip, and even shoulder surgeries. Please join us September 10-12th for DeviceTalks's LIVE Connected Health webinar series. Register at no cost: https://event.on24.com/wcc/r/4613481/E930EFFA706588C378BEAA97824C7CE2/5516160 Tune in and subscribe to DeviceTalks on all major podcast channels and follow youtube.com/@DeviceTalks to ensure you never miss an episode. Thank you for listening to the Ortho Innovation Talks podcast, featuring Zimmer Biomet!

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Steward Health plans to lay off over 1,200 workers in Massachusetts and close two hospitals. Walgreens has reduced its stake in Cencora for $1.1 billion. The cost of healthcare data breaches is nearly $10 million in 2024, making healthcare the most expensive industry for data breaches. Employers are enhancing healthcare benefits despite rising costs, and Medicare has finalized a higher 2.9% inpatient payment rate for 2025. Virtual reality, robotics, and AI are transforming patient engagement, staff burnout, and clinical decision-making in the healthcare industry. Hospitals remain dissatisfied with Medicare's final rule despite the bump in payment rates.On August 5th, J&J launched the Velys spine surgical robotics and navigation platform, while Inspire received FDA approval for obstructive sleep apnea neurostimulator therapy. Philips is suing an independent lab over alleged errors in CPAP foam tests. Compliance hurdles with the FDA's lab developed test rule raise concerns about patient harm. The board of 23andMe rejected CEO Wojcicki's take-private proposal. J&J aims to compete with Stryker and Zimmer Biomet with its new surgical robotics portfolio. Inspire plans to launch its neurostimulator therapy device late in 2024. Philips claims an independent lab overestimated the threat of CPAP foam, leading to unnecessary recall efforts.Bristol Myers has halted Tigit drug research, while Lilly has resolved the shortage of Zepbound and Mounjaro. Biotech IPOs are vital for industry growth, with companies like Os Therapies and Actuate Therapeutics making moves in the market. Cell therapy is advancing in cancer care despite limited uptake, with biotech companies investing in its improvement. Pfizer discontinued late-stage gene therapy development for Duchenne Muscular Dystrophy (DMD), but other companies like RegenxBio and Capricor Therapeutics are making progress with their therapies. Oncology research is introducing new treatments like cell and gene therapies, revolutionizing cancer treatment.BioNTech reported a significant increase in losses in the second quarter of 2024, jumping to nearly $885 million compared to $208.5 million last year. The company is focusing on oncology amidst the impact of COVID-19. Lilly's drugs Mounjaro and Zepbound are no longer in shortage, according to the FDA. Bristol Myers Squibb is backing out of a $1.5 billion deal with Agenus for a bispecific antibody program, while Bayer's finerenone met its primary endpoint in a phase III heart failure trial. The pharmaceutical industry continues to see developments in various therapeutic areas, including Alzheimer's disease and rare diseases.Support the Show.

Dr. Jesse Otero, Orthopedic Surgeon, OrthoCarolina, discusses the challenges of performing total hip replacements in ambulatory surgery centers (ASCs) and the role technology plays in overcoming them. He explores the advantages of automated impaction devices, like the Hammr, for surgeons, patients, and long-term surgical practice.This episode is sponsored by Zimmer Biomet.

Dr. Jesse Otero, Orthopedic Surgeon, OrthoCarolina, discusses the challenges of performing total hip replacements in ambulatory surgery centers (ASCs) and the role technology plays in overcoming them. He explores the advantages of automated impaction devices, like the Hammr, for surgeons, patients, and long-term surgical practice.This episode is sponsored by Zimmer Biomet.

Join us this week on the Treasury Career Corner podcast for an insightful conversation with Pradipto Bagchi, Treasurer at Zimmer Biomet, as we discuss his treasury career journey and the challenges he faced during the COVID-19 pandemic.Pradipto Bagchi is the Treasurer at Zimmer Biomet, a global medical technology leader. With his expertise in treasury and capital markets, he has successfully navigated complex financial situations and played a crucial role in stabilizing the company's balance sheet during the pandemic.In this episode, Pradipto shares his career journey, starting from his engineering background to consulting and technology, and eventually finding his passion for finance and treasury. He highlights the importance of formal education and the value of diverse experiences in shaping a successful career. Pradipto also discusses his roles at IBM, Pepsi, Allergan, and his current position at Zimmer Biomet. Emphasizing the significance of treasury plus, where treasury professionals go beyond their core responsibilities to add value to the company in areas such as investor relations, FP&A, and business development. He also shares insights on managing global teams and the importance of building personal connections with team members.Key Takeaways:Don't be afraid to ask questions and admit when you don't know something.Keep an open mind and explore different areas to find what you truly enjoy.Treasury plus is about going beyond core treasury responsibilities and becoming a strategic partner to the company.Build personal connections with team members by meeting them in person and understanding their backgrounds and cultures.Seek out diverse experiences to shape a well-rounded career.You can connect with Pradipto Bagchi on LinkedIn. Are you interested in pursuing a career within Treasury?Whether you've recently graduated, or you want to search for new job opportunities to help develop your treasury career, The Treasury Recruitment Company can help you in your search for the perfect job. Find out more here. Or, send us your CV and let us help you in your next career move! If you're enjoying the show please rate and review us on whatever podcast app you listen to us on, for Apple Podcasts click here!To subscribe to the Treasury Career Corner podcast via:Apple

This week, Dr. Scott Sigman is joined by Ivan Tornos, CEO of Zimmer Biomet. Here, they discuss the culture he's developed at Zimmer Biomet, his missionary vision, his accessible philosophy, and more.

In today's episode of Executive Decisions, host Sarah Delahanty sits down with Todd Davis who shares his rich career history from building airplanes to his executive career in the orthopedic industry. Todd reflects on his journey from managing older union workers while still in his 20's to his transition into executive leadership roles. He emphasizes the importance of work ethic, persistence, and building relationships, sharing valuable insights from his experiences. Todd also discusses his post-executive life, engaging in mentorship, fundraising efforts for his community, and continuous personal development through reading diverse materials. Through his story, listeners gain valuable lessons in leadership, adaptability, and the importance of work-life integration.   About our guest, Todd Davis: Todd is a seasoned leader with over three decades of experience in the orthopedic industry, particularly in driving the success of major knee franchises for some of the world's largest companies. From Sales and Marketing to Product Development, Strategy, and M&A, Todd has demonstrated his visionary leadership skills by accelerating growth opportunities and fostering world-class teams and cultures. After retiring from his role as President and General Manager of the Global Knee Business at Zimmer Biomet in July 2019, Todd has redirected his focus towards the startup landscape within the Medtech sector. He currently serves as an Independent Board Director for PeekMed Health, a Board Observer for Enhanced Medical Nutrition, and a Board Director for JointVue, while also providing consulting expertise for companies like Smith+Nephew, Canary Medical, Maxx Ortho, Kinamed, Kneevoice, and various other OEMs.   Summary and highlights from the show: Todd Davis had a formative experience working full-time at Rockwell International while still going to school. He was promoted into a managerial role in his mid to late 20's, leading teams of older aircraft mechanics. Davis learned to lead by example and develop a strong work ethic during this time, working 70 hours a week while pursuing his education at night. His transition to orthopedics involved leading a team of older individuals in the customer service group at Zimmer Biomet, where he applied his leadership skills and learned to be persistent in pursuing his goals. Todd emphasizes the importance of not chasing money but rather finding something you enjoy and working hard at it, as advised by his father. He shares his experience of persistence in pursuing opportunities, such as transitioning into marketing at Zimmer Biomet despite initial rejection from the vice president of marketing. Building relationships is crucial in the orthopedic industry, and Todd highlights the impact of handwritten thank-you notes in making lasting connections. Todd reflects on the importance of work-life balance, which he prioritized by scheduling family events and delegating responsibilities as he advanced in his career. Transitioning to board roles and mentoring startups has been rewarding for Todd, allowing him to leverage his experience and make a meaningful impact. He discusses his involvement in community initiatives, such as leading a capital campaign for a school expansion, and his interest in personal development through reading. Todd finds inspiration and leadership insights from various sources, including spiritual books, business literature, and perspectives from different industries like the restaurant business.   Connect with Todd Davis: Email About SYM Financial and the Executive Decisions Podcast: Executive Decisions is a podcast designed for current and aspiring business leaders, offering an in-depth look at the evolving nature of executive roles. Hosted by SYM Financial Advisors Principal and Senior Financial Advisor Sarah Delahanty, the show delves into the personal and professional journeys of its guests, exploring the challenges they've overcome and the learning experiences that have shaped their paths to success. The podcast provides insights into how executives manage the increasing complexity of both their professional and personal lives. Featuring a range of guests from diverse industries, each episode aims to enlighten listeners on the continuous state of learning and adaptation necessary for effective leadership. Whether discussing career progression, leadership strategies, or personal growth, Executive Decisions is a valuable resource for anyone interested in the multifaceted world of executive leadership.   Disclosure: Certain links above are to third-party sites and are not affiliated with SYM Financial Corporation (“SYM”). SYM is an independent investment adviser registered under the Investment Advisers Act of 1940, as amended. Registration does not imply a certain level of skill or training. More information about SYM including our investment strategies, fees and objectives can be found in our ADV Part 2, which is available upon request.

Embark on a journey into the heart-pounding, adrenaline-charged world of medical sales with your host, Samuel Adeyinka, and special guest, Chad Casey, VP of Sales at Zimmer Biomet. Chad is currently the Vice President of Sports Medicine, Extremities, Trauma, and ASC strategy for Zimmer Biomet Carolinas. He is a successful sales executive with over 23 years of experience.  Discover what it takes to make it in the high-stakes arenas of sports medicine, trauma, and orthopedics. In this episode, we navigate the challenges and triumphs within these specialties, shedding light on the evolving influence of Ambulatory Surgery Centers and Medicare on the sales landscape. As we dissect the demands of the job, from the urgency of trauma care to the precision of foot and ankle surgery, we uncover the strategies that enable sales professionals to excel in this dynamic field. The path to success in medical device sales is not for the faint of heart, as we candidly discuss the grit and commitment required to forge a career in this industry. We confront the myth of easy success head-on, highlighting the steep personal and financial investments needed. This conversation delves into the complexities of proving one's worth in a fiercely competitive environment and the increased expectations from today's sales reps. By demystifying the sales process, we reveal how top performers use storytelling, build trust, and demonstrate the value of lifelong learning and mentorship. Chad Casey shares his own remarkable career trajectory, from military service to his rise through the medical device sales ranks, embodying the virtues of resilience and adaptability. We discuss the delicate balance between professional ambitions and personal life, offering listeners valuable advice for maintaining that equilibrium. Whether you're intrigued by the nuances of working for large versus small companies or seeking mentorship for your own career advancement, this episode is packed with insights from a seasoned expert who understands the transformative power of dedication and genuine connection in the healthcare sales industry.   The CE experience for this Podcast is powered by CMEfy - click here to reflect and earn credits: https://earnc.me/tSi2M4

Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here's what you need to know for today, February 23, 2023. Check out the show notes for links to the stories we discussed today at MassDevice.com/podcast. ClearPoint Neuro's latest software received FDA clearance and the company announced the first cases. Fast Five hosts Danielle Kirsh and Sean Whooley talk about what the software does and what executives are saying. The FDA is warning people not to use smartwatches and smart rings to measure blood glucose. Learn why the FDA is warning on this and what consumers should do. Enovis's stock rose this week on Street-beating fourth-quarter results as it returns to profit. Whooley breaks down the financial performance of the orthopedic company. Zimmer Biomet's ROSA Shoulder surgical robot. The Fast Five hosts talk about what the surgical robot does and what it gives physicians. A former Mazor VP has been convicted of insider trading. Hear more about this case and how the federal government stumbled upon this case. BONUS: Jill Biden launches $100M initiative to transform women's health research

This week we interviewed Steve C de Baca. Steve is Executive Vice President and Chief Patient Safety & Quality Officer of Royal Philips. He brings more than 30 years of quality and regulatory affairs (QRA) experience in the medical technology industry. Prior to joining Philips, Steve served as the EVP of QRA for Cardinal Health, supporting the $185 bn enterprise and was a member of the Operating Committee. Prior to this, Steve served as VP of QRA for Orthopedics and Americas for Zimmer Biomet, where he was responsible for supporting multiple business segments as well as the Americas region for international regulatory and compliance. Earlier in his career, he served as the SVP of Quality, Regulatory & Clinical Affairs for the Danaher Diagnostic platform, which includes the four separate operating companies of Beckman Coulter Diagnostics, Leica Biosystems, Radiometer & Cepheid. Prior to that, Steve was with Boston Scientific for over eight years in progressively senior strategic roles, the last of which was VP of Quality, for the Cardio, Rhythm, and Vascular (CRV) and the Neuromodulation businesses. Additionally, Steve served as an industry board member and instructor for six years for the Regulatory Affairs master's degree program at St. Cloud State University. He earned a bachelor's degree in engineering and industrial technology and an MBA, both at California State University Long Beach.   He lives in Minnesota and has been married to his wife Katherine for over 24 years. They are proud of their son Carson who is currently attending Northeastern University in Boston.

Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here's what you need to know for today, February 14, 2024. Check out the show notes for links to the stories we discussed today at MassDevice.com/podcast. Wandercraft won FDA clearance for its exoskeleton for people with spinal cord injuries. Fast Five hosts Sean Whooley and Danielle Kirsh explain the details of the exoskeleton and some of its features. The FDA has cleared Masimo's over-the-counter fingertip pulse oximeter. Hear more about what the device does and where it will be available. ResMed launched new bilevel sleep respiratory devices. The Fast Five hosts discuss the new devices and ResMed's goal when developing them. Smith+Nephew is touting new artificial intelligence features for its Cori surgical robot. Learn more about the latest features of the robot. Zimmer Biomet signed a health equity pledge. Whooley talks about the pledge and how the company is taking strides toward that goal.

In today's episode, I sit down with Dr. Peter Bonutti to talk about the ways in which technologies are revolutionizing our understanding of the brain, and how they may be used to treat crippling brain disorders such as stroke and seizures. Dr. Peter Bonutti, M.D. is a surgeon, inventor, author, professor, consultant, and entrepreneur. He is the founder of Bonutti Research, a medical device incubator that has developed products and technology used around the world. He maintains his clinical and surgical practice, focusing on the integration of robotics into surgical procedures. He is the founder and president of Releave, a company whose technology has already been clinically proven in more than 700 patients for the treatment of a brain related disorder. Realeve's ultimate goal is to solve one of the critical remaining barriers in brain health: the ability to bypass the brain's natural barrier preventing the delivery of effective drugs for stroke, cancer treatment, and other degenerative orders. Dr. Bonutti is a pioneer in Minimally Invasive Surgery, has over 500 patents and applications, more than 700 licenses and multiple FDA-approved products to date. Major corporations leveraging his technology include Hitachi, Kyphon, Covidien, US Surgical, Biomet, Arthrocare, Synthes, Zimmer/Biomet and Stryker. He is a prolific speaker, lecturing internationally, and has trained over 100 surgeons on his surgical techniques. In his career, Dr. Bonutti has received more than a dozen industry honors and awards for his achievements. Dr. Bonutti earned his medical degree at University of Cincinnati College of Medicine and completed his Orthopaedic Surgery Residency at Cleveland Clinic Foundation with international fellowships in Canada, Australia, and Austria.

839: The healthcare industry is constantly evolving and finding uses for new and emerging technologies. Zeeshan Tariq, CIO at Zimmer Biomet, shares his experience exploring the use cases of AI in this latest episode and explains his metrics-based approach to driving that transformation internally. Zeeshan describes the company's transition from purely medical devices to a full healthcare solutions provider and what new operating models came along with that transition. He details the company's adoption of KPIs for every facet of performance and why it has led to immense success in benchmarking over the last few years. Zeeshan also discusses the value of artificial intelligence, the advantages of collaborating with strategic partners, and the challenges of collaborating with a global team. Finally, Zeeshan looks ahead at the trends in emerging technologies that are on his radar and the advice he has for those early in their careers.

839: The healthcare industry is constantly evolving and finding uses for new and emerging technologies. Zeeshan Tariq, CIO at Zimmer Biomet, shares his experience exploring the use cases of AI in this latest episode and explains his metrics-based approach to driving that transformation internally. Zeeshan describes the company's transition from purely medical devices to a full healthcare solutions provider and what new operating models came along with that transition. He details the company's adoption of KPIs for every facet of performance and why it has led to immense success in benchmarking over the last few years. Zeeshan also discusses the value of artificial intelligence, the advantages of collaborating with strategic partners, and the challenges of collaborating with a global team. Finally, Zeeshan looks ahead at the trends in emerging technologies that are on his radar and the advice he has for those early in their careers.

The EU MDR 2017/745 was extended but does this change something for you? Do you need to apply to your notified body later? What can be the promise made by your Notified Body? Can they advice you? Pritam from TÜV SÜD will be answering my question without any taboo. So don't hesitate also to go to the show notes and see his details as at the end of the video he will be making you a promise. So don't miss this opportunity. And if you need some support for your Notified Body application contact us at Easy Medical Device. Who is Monir El Azzouzi? Monir El Azzouzi is a Medical Device Expert specializing in Quality and Regulatory Affairs. After working for many years with big Healthcare companies, particularly Johnson and Johnson, he decided to create EasyMedicalDevice.com to help people better understand Medical Device Regulations worldwide. He has now created the consulting firm Easy Medical Device GmbH and developed many ways to deliver knowledge through videos, podcasts, online courses… His company also acts as Authorized Representative for the EU, UK, and Switzerland. Easy Medical Device becomes a one-stop shop for medical device manufacturers that need support on Quality and Regulatory Affairs. Who is Pritam Mekala?  Pritam Mekala is an enthusiastic, ambitious, and motivated medical device expert. Born in India, grew up in America, studied in the US, and currently living and working in Toronto, Canada, Pritam is an ensemble of multi-national, multi-cultural and multi-linguistic personality. He currently works at TÜV SÜD, as a Product Expert & Auditor in their Medical Health Sciences (MHS) Product Assessment Team (PAT).  Before joining the Notified Body team, Pritam worked as a was project engineer at Abbott on their infamous BinaxNOW - COVID Test Kit project. He also worked at other notable medical device manufacturers such as Medtronic, Covidien, Zimmer Biomet etc.   On the education front, Pritam graduated from the Oklahoma State University with a master's in mechanical and aerospace engineering with research & specialization in Biomedical Engineering.  As a representative of Notified Body, TÜV SÜD, Pritam can help you facilitate:  Free 30minute Call (at no additional cost) *NOT CONSULTATION*  Free Budgetary quote (for review & comparison)  Free Technical Documentation Guidance (at no additional cost)  Links from the Video Profile LinkedIn:  https://www.linkedin.com/in/pritam-mekala/ Email: Pritam.mekala@tuvsud.com  Company website: https://www.tuvsud.com/en-us  Relevant MDCG Announcements:  https://health.ec.europa.eu/system/files/2023-11/mdcg_2022-11_en.pdf  https://health.ec.europa.eu/system/files/2023-07/mdr_proposal_extension-q-n-a.pdf  https://health.ec.europa.eu/latest-updates/mdcg-2022-14-transition-mdr-and-ivdr-notified-body-capacity-and-availability-medical-devices-and-2022-08-26_en  TÜV SÜD Structure Dialogue:   https://ts.tuvsud.com/rs/819-PVY-502/images/T%C3%9CV%20S%C3%9CD%20Structured%20Dialogue%20-%20customer%20presentation.pdf?version=0&mkt_tok=ODE5LVBWWS01MDIAAAGO-2Fg5uIG2idWOUuPQkEspBBKLOHU1vf9rLoMqzR2t_pnXJguMMpidTQA5rQbAJ-uIcPpYp3S4QS8SV6R1wE2GeN8IJNMyV2HJf24YyQdGxo Social Media to follow Monir El Azzouzi Linkedin: https://linkedin.com/in/melazzouzi Twitter: https://twitter.com/elazzouzim Pinterest: https://www.pinterest.com/easymedicaldevice Instagram: https://www.instagram.com/easymedicaldevice

In the inaugural episode of Ortho Innovation Talks: Zimmer Biomet, Rachel Ellingson, SVP and Chief Strategy Officer at Zimmer Biomet, shares insights into the company's growth strategy, emphasizing that growth can be achieved not only through addition - like innovation and acquisition - but also through subtraction, such as exiting lower growth, non-core businesses. In the episode, Ellingson discusses the decision to spin off Zimmer Biomet's spine and dental businesses and the significant undertaking required to create a new public company, which required integrating and then disintegrating business segments, building corporate infrastructure, and establishing a dedicated leadership team for the new entity - a major initiative involving over 500 people and a dedicated separation management office. Lastly, Ellingson discusses what's next in Zimmer Biomet's growth strategy, citing a balance between internal innovation and M&A and noting that the company plans to launch over 40 new products in the next 36 months, focusing on markets with at least 4% growth. Thank you to our season one sponsors, AcuityMD and Millstone Medical! Tune in and subscribe to DeviceTalks on all major podcast channels and follow youtube.com/@DeviceTalks to ensure you never miss an episode. WATCH and LISTEN below, thank you for supporting Ortho Innovation Talks!

Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here's what you need to know for today, Dec. 8, 2023. Check out the show notes at massdevice.com/podcast. Beta Bionics became the second company in as many days to launch an automated insulin pump with the Dexcom G7 CGM. Fast Five hosts Jim Hammerand and Sean Whooley dive into the latest news and break down the key features of the iLet bionic pancreas. Distalmotion selected a former Zimmer Biomet executive to take over as its new CEO. The hosts look into the background of the new figure in the corner office and discuss the Dexter surgical robot platform as the company prepares for its next phase of growth. BD has a new alternative to the traditional venous blood drawing method following FDA clearance for its MiniDraw device. Hammerand and Whooley explain what sets this device apart from other methods and why it could usher in a new era of diagnostics. Medtronic made waves earlier this year when it agreed to acquire insulin patch pump maker EOFlow, but that deal is now off after the medtech giant terminated their acquisition agreement. The hosts discuss the reasons behind Medtronic's decisions and the potential ramifications on the insulin delivery market. Edwards is the latest big-name medtech company to join the spin-off trend, announcing plans to spin its critical care business. Hammerand and Whooley take a look at Edwards' reasoning behind the decision and the areas in which the company now plans to focus once it completes the separation.

In this episode, George Saiz explores the essence of his book, "We Started with Respect," touching on its unique message, the significance of respect, overlooked key elements for cultural change, and personal writing insights. What You'll Learn: 1. Why a book on culture - there are so many out there? What important message do you bring? 2. Why the book title of "We Started with Respect," what's important about that to you? 3. Your front book cover says it's A Novel, but the word "Novel" is crossed out and replaced with the word "Blueprint." Tell us about that. 4. In your book, the team adopts seven key elements of the culture that they want to develop. I recognize that they're all important, but which one or ones do you think are overlooked and yet are key to successfully transforming the company culture? 5. What is something you learned over the course of writing this book? About the Guest: George Saiz enjoys sharing leadership strategies from his experience as a medical device executive with Johnson & Johnson, Zimmer-Biomet, DJO Global and MicroAire. Combined with the best practices he observed as President & CEO of The Association for Manufacturing Excellence, he's convinced of the importance of including people in all business equations. Now, as a writer, keynote speaker, and coach, he promotes enterprise excellence through a people-centric culture to the next generation of business leaders.  Links: ⁠⁠Click here for more information on George Saiz⁠ ⁠⁠Click here for more information on "We Started With Respect"⁠ --- Support this podcast: https://podcasters.spotify.com/pod/show/leansolutions/support

When you're making decisions, professional or personal, what's your north star? How many people know your north star? How many of your colleagues know what you've built your life around? There's this idea, of leaving home at home and only bringing into work your work self. Can you really leave at home what fuels you and drives you? When Lori Winkler at the top of Johnson and Johnson's HR department, she was a high achiever, sure – but as you'll hear her say, no one really know who Lori Winkler was. They just knew what she did, and that she did it well. But that wasn't Lori. So who is Lori today, as the Chief Human Resources Officer for Zimmer Biomet? You'd be surprised how much Bruce Springsteen is involved.  

Get your team's full effort.You can't lead a team that's not committed. What truly separates teams today is how much they buy-in to the mission and their willingness to invest their discretionary effort. You'll love the mindset of Ivan Tornos, CEO and President of the orthopedics giant, Zimmer Biomet, who is working to transform the company and an entire industry. They are a 96-year-old company in 125 countries with a mission to alleviate pain and improve the quality of life around the world.Discover the actionable strategies, real-life success stories, and leadership secrets that can transform your team's dedication and propel your organization to the next level. Ivan has 30 years of experience in medtech working around the globe including senior leadership at BD, Medtronic, Baxter, and Johnson and Johsnon with MBAs from The Wharton School, The University of Miami and undergraduate degree from The University of Georgia.LinkedIn Profile https://www.linkedin.com/in/ivantornos/Company Link: https://www.zimmerbiomet.com/enWhat You'll Discover in this Episode:The leadership trait that Ivan most admires.How to find great mentors and sponsors.Cleaning tanning beds - What it taught him about leadership.The 3 C's he leads by.A twist in his career that accelerated his growth.-----Connect with the Host, #1 bestselling author Ben FanningSpeaking and Training inquiresSubscribe to my Youtube channelLinkedInInstagramTwitter

Admetsys this week won FDA breakthrough designation for its automated glucose control technology. Fast Five hosts Sean Whooley and Danielle Kirsh discuss what the glucose control system does and what executives are saying. Moximed has implanted its first Misha knee implantable shock absorber in the U.S. Find out what an implantable shock absorber is and what doctors think about it.  GE HealthCare and Mass General are collaborating on AI algorithms to predict missed care opportunities, expanding on its existing 10-year partnership. Whooley explains the aim of the collaboration and what the artificial intelligence algorithms will be used for.  Zimmer Biomet announced several executive appointments just days after former CEO Bryan Hanson left. Tune in to discover who joins the executive team and what the new CEO says about the shuffling.  Another diabetes acquisition is in the news – this time, Abbott is acquiring Bigfoot Biomedical. The acquisition follows an established partnership between the companies. Whooley explains their prior partnership and other acquisition news in the diabetes sector. Check out the show notes for links to the stories we discussed at MassDevice.com/podcast.

This isn't Bertin Nahum's first surgical robotics rodeo. The CEO of Quantum Surgical previously co-founded, led and ultimately sold surgical robotics pioneer Medtech S.A. to Zimmer Biomet. Now, he's leading several members of that founding team as Quantum Surgical develops a next generation of surgical robot to enable easier removal of cancerous tumors. Nahum brings great insight and perspective to the topic of surgical robotics, which is why he'll sit on a panel of surgical robotic company CEOs and provider represents to discuss what surgical robotic systems of the future may look like. Register at DeviceTalks.com. Joining co-hosts Chris Newmarker and Tom Salemi is Danielle Kirsh, senior editor of MassDevice, to review a few of the highpoints of the current Medical Design and Outsourcing issue of the Big 100. We'll talk about headcounts, R&D spends and CEO salaries. You can find the issue of the Big 100 here. https://www.medicaldesignandoutsourcing.com/september-2023-medtech-big-100-largest-device-companies/ Thanks for listening to the DeviceTalks Weekly Podcast. You can subscribe to the DeviceTalks Podcast Network on any major podcast application.

Medtronic's first-quarter results are in, and they were ahead of the consensus forecast on Wall Street. Fast Five hosts Sean Whooley and Danielle Kirsh discuss the company's performance, what contributed to its growth and how each segment performed. Wenzel Spine has received FDA clearance for expanded indications of its primaLOK SP system for spinal fusion procedures. Hear how the system works, what some of the features are and what doctors think about using the device. Surgical robotics continue to innovate in medtech as Levita Magnetics won FDA clearance for its magnetic-assisted robot. Tune in to discover how the minimally invasive surgical platform works and how surgeons can benefit from using it. Philips issued an urgent field safety notice for some of its imaging systems due to an issue that could lead to unintended radiation. Whooley shares the details of the issue, which systems are affected and what potential outcomes could arise if not addressed. Personnel changes within the industry continue and today's episode covers a pretty big move – Zimmer Biomet's CEO is leaving the company to join another big player in medtech. Find out where he is going, as well as some of his accomplishments at ZB in today's episode. Also, hear who is taking over as CEO at Zimmer Biomet, as well as some other executive changes within ZB and 3M. Check out the show notes for links to the stories we discussed today at MassDevice.com/podcast.

Tune in for today's industry updates.

A truly inspiring conversation with the COO of Zimmer-Biomet, Ivan Tornos!  Truly a successful summiteer of so many mountains in our  industry,  what can we learn from this accomplished climber to help us on our journey?   Nearly 3 decades of success in the medical space delivering on commitments at every turn, you'll want to take notes on this episode as he shares:-Device Rep predictors of success -What are the 4 ways in which we approach problems-The difference between "mentorship" and "sponsorship"-The value of thinking beyond the Operating Room.......and much, much more!!Health Care Technology Award: https://thehealthcaretechnologyreport.com/the-top-25-healthcare-technology-leaders-of-new-york-for-2023/Careers at Zimmer Biomet: https://www.zimmerbiomet.com/en/about-us/careers.html"I say buy ZMH" https://www.cnbc.com/2023/07/25/cramers-lightning-round-zimmer-biomet-is-a-buy.html"Belief" eventually affects "Destiny"....what belief systems aid us in our summit attempts, and which have the potential to keep us stuck at basecamp?   Support the show

It's been a little more than a year since ZimeVie was launched from Zimmer Biomet. The dental and spine specialist has had to overcome some tough obstacles and find its footing. ZimVie's CEO, Vafa Jamali returns to Let's Talk Medtech to discuss the company's growth, tribulations, success, and why Europe has become a fertile market. You don't want to miss this exciting episode of Let's Talk Medtech.

Zimmer Biomet Holdings, Inc., Q2 2023 Earnings Call, Aug 01, 2023

Kenneth Tripp, Senior Vice President of Global Operations and Logistics at Zimmer Biomet, believes that resilience is not just about surviving; it's about thriving in the face of adversity, adapting to change, and discovering the untapped strength within ourselves. Join us in this captivating episode as we feature Ken Tripp to discuss resilience and the power of adaptability. Ken shares the secrets to adapting and bouncing back from life's toughest challenges and uncovering the power within you to navigate through difficult times. He emphasizes how resilience is not an inborn trait but a skill that can be nurtured and developed over time. He shares the continuous process of building resilience, where every experience serves as a lesson and a stepping stone toward personal growth. Ken explains the transformative mindset of resilience—a beacon of positivity, hope, and unwavering belief in your ability to overcome any obstacle. Tune in now and learn how to embrace setbacks as opportunities to learn, adapt, and find creative solutions.Show Notes:02:25 – Cryptologic Technology And 9/1118:18 – Resilience In Small Companies23:54 – The Navy Experience34:53 – Failure And Accountability42:34 – For The Love Of Movies59:02 – Adaptability: There's No Roadmap For The Future

Last call for DeviceTalks Boston! In this episode we'll preview our upcoming conference by talking with Paul Grand, CEO of Medtech Innovator, Rebecca Whitney, SVP at ZimView, Holly Scott and Joe Mullings at the Mullings Group. We'll have Fastball Pitches from two Medtech Innovator companies that will be presenting on May 10-11. Register at DeviceTalks.com. Use the code DTWeekly25 to save 25% Chris Newmarker delivers his #newmarkernewsmakers featuring 3M, Zimmer Biomet, Stryker, Medtronic and Casana, maker of a now FDA-approved smart toilet seat. Thanks for listening to the DeviceTalks Weekly Podcast. Subscribe to the DeviceTalks Podcast Player on any major podcast application.